| 14.025 0.605 (4.51%) | 05-04 12:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.2  |
1-year : | 23.17 |
| Resists | First : | 17.29 |
Second : | 19.84 |
| Pivot price | 14.13 |
|||
| Supports | First : | 13.18 | Second : | 10.96 |
| MAs | MA(5) : | 13.55 |
MA(20) : | 14.27 |
| MA(100) : | 26.62 |
MA(250) : | 22.36 |
|
| MACD | MACD : | -2.3 |
Signal : | -2.8 |
| %K %D | K(14,3) : | 19.8 |
D(3) : | 13.3 |
| RSI | RSI(14): 29.8 |
|||
| 52-week | High : | 34.29 | Low : | 11.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VRDN ] has closed above bottom band by 42.0%. Bollinger Bands are 59.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.7 - 13.77 | 13.77 - 13.82 |
| Low: | 13.05 - 13.15 | 13.15 - 13.22 |
| Close: | 13.29 - 13.43 | 13.43 - 13.54 |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Sun, 03 May 2026
MSN Money - MSN
Sun, 03 May 2026
Viridian Therapeutics (VRDN) price target decreased by 11.71% to 36.18 - MSN
Sat, 02 May 2026
MSN Money - MSN
Wed, 22 Apr 2026
Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year - Yahoo Finance
Tue, 21 Apr 2026
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% - Yahoo Finance
Tue, 21 Apr 2026
Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026 - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 1.0215e+008 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 8,230 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.6294e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -95 % |
| Return on Assets (ttm) | 643.1 % |
| Return on Equity (ttm) | -27.7 % |
| Qtrly Rev. Growth | 7.085e+007 % |
| Gross Profit (p.s.) | 71.81 |
| Sales Per Share | -42.38 |
| EBITDA (p.s.) | -2.31103e+008 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -276 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.33 |
| Price to Cash Flow | 2.78 |
| Dividend | 0 |
| Forward Dividend | 1.066e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|